Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Cidofovir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.98 |
| ▸ | TYMP | P19971 | 3/20 | 0.49 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cidofovir Anhydrous SCHEMBL2946561 | 1.00 | SLC22A6 (1.00) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL12988503 | 1.00 | SLC22A6 (1.00) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL151807 | 0.99 | FGFR1 (1.00) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL3948 | 0.99 | FGFR1 (1.00) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL1389452 | 0.99 | FGFR1 (1.00) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL14682730 | 0.99 | FGFR1 (1.00) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL934593 | 0.98 | FGFR1 (0.98) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL20770422 | 0.98 | FGFR1 (0.98) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL28935227 | 0.98 | FGFR1 (0.98) | SLC22A6FGFR1TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL27629017 | 0.98 | FGFR1 (0.98) | SLC22A6FGFR1TYMPHPRT1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326725-A1 | PI4-Kinase Inhibitors and Methods of Using the Same | UNIV LELAND STANFORD JUNIOR (US) | 2025-10-23 | — | — | US | disclosed |
| US-12415788-B2 | PI4-kinase inhibitors and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-11884657-B2 | PI-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230136702-A1 | Inhibitors of Human Herpesviruses | THE GOVERNORS OF THE UNIVERSTIY OF ALBERTA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20220280513-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-09-08 | — | — | US | disclosed |
| US-20220153711-A1 | P14-Kinase Inhibitors and Methods of Using the Same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| EP-3941909-A1 | PI4-KINASE INHIBITORS AND METHODS OF USING THE SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220017507-A1 | PI-Kinase Inhibitors with Anti-Infective Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-20 | — | — | US | disclosed |
| US-11091472-B2 | PI-kinase inhibitors with anti-infective activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2021011572-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| US-20050187183-A1 | Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases | HAMPRECHT, KLAUS (DE) | 2005-08-25 | — | — | US | disclosed |
| US-6894056-B2 | Evaluating the patient for serologic evidence of epstein-barr virus and cytomegalovirus, obtaining serum, measuring immunoglobulin antibodie levels by measuring nonstructural epitopes for incomplete virus multiplication and classifying | LERNER A MARTIN (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| US-20040072144-A1 | Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome | LERNER A MARTIN (US) | 2004-04-15 | — | — | US | disclosed |
| US-6537997-B1 | Administration of antiviral agents. Based on clinical tests, chronic fatigue syndrome is a persistent herpes virus infection including incomplete virus multiplication and thus administration of antiviral agents are shown to alleviate the | LERNER A MARTIN (US) | 2003-03-25 | — | — | US | disclosed |
| US-6399622-B1 | EVALUATING PATIENT FOR EVIDENCE OF EPSTEIN-BARR VIRUS AND CYTOMEGALOVIRUS, ADMINISTERING ANTIVIRAL AGENTS | LERNER A MARTIN (US) | 2002-06-04 | — | — | US | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020037501-A1 | Evaluating patient for evidence of epstein-barr virus and cytomegalovirus, administering antiviral agents | LERNER A MARTIN (US) | 2002-03-28 | — | — | US | disclosed |
| US-6258818-B1 | ADMINISTERING VIRICIDES AND DETECTION, CARDIOVASCULAR DISORDERS | LERNER A MARTIN (US) | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326725-A1 | PI4-Kinase Inhibitors and Methods of Using the Same | PI4KB, PI4KA, PI4K2A | SLC22A6 4003/4885FGFR1 4016/4885TYMP 311/4885 |
| US-20230136702-A1 | Inhibitors of Human Herpesviruses | RPL5, RPL35, HAVCR2 | SLC22A6 4406/4885FGFR1 4169/4885TYMP 18/4885 |
| US-20050187183-A1 | Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases | PHOSPHO1, PNP, ABHD16A | SLC22A6 299/4885FGFR1 2132/4885TYMP 20/4885 |
| US-11091472-B2 | PI-kinase inhibitors with anti-infective activity | PIP4K2A, PIP5K1A, PIP4K2C | SLC22A6 4426/4885FGFR1 4186/4885TYMP 358/4885 |
| US-11884657-B2 | PI-kinase inhibitors with anti-infective activity | PIP5K1A, PIP4K2A, PI4KB | SLC22A6 4279/4885FGFR1 3823/4885TYMP 174/4885 |
| US-12415788-B2 | PI4-kinase inhibitors and methods of using the same | PI4KB, PI4KA, PI4K2A | SLC22A6 4003/4885FGFR1 4016/4885TYMP 311/4885 |
| US-20220153711-A1 | P14-Kinase Inhibitors and Methods of Using the Same | PI4KB, PI4KA, PI4K2A | SLC22A6 4150/4885FGFR1 3768/4885TYMP 479/4885 |
| US-20220280513-A1 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | EIF2AK2, RNGTT, RNMT | SLC22A6 2020/4885FGFR1 4506/4885TYMP 13/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | SLC22A6 238/4885FGFR1 2478/4885TYMP 4472/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | SLC22A6 1108/4885FGFR1 4534/4885TYMP 418/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | SLC22A6 1488/4885FGFR1 3001/4885TYMP 3788/4885 |
| US-20220017507-A1 | PI-Kinase Inhibitors with Anti-Infective Activity | PIP4K2A, PIP5K1A, PIP4K2C | SLC22A6 4413/4885FGFR1 3981/4885TYMP 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.